Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

650 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).
Chanan-Khan A, Miller KC, Takeshita K, Koryzna A, Donohue K, Bernstein ZP, Mohr A, Klippenstein D, Wallace P, Zeldis JB, Berger C, Czuczman MS. Chanan-Khan A, et al. Among authors: mohr a. Blood. 2005 Nov 15;106(10):3348-52. doi: 10.1182/blood-2005-02-0669. Epub 2005 Jul 28. Blood. 2005. PMID: 16051743 Free article. Clinical Trial.
Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, Skipper M, Brown K, Miller K, Wentling D, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-López AJ, Bernstein SH. Czuczman MS, et al. Among authors: mohr a. Semin Oncol. 2002 Feb;29(1 Suppl 2):36-40. Semin Oncol. 2002. PMID: 11842387 Review.
Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH. Czuczman MS, et al. Among authors: mohr a. J Clin Oncol. 2005 Feb 1;23(4):694-704. doi: 10.1200/JCO.2005.02.172. J Clin Oncol. 2005. PMID: 15681517 Clinical Trial.
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS. Chanan-Khan A, et al. Among authors: mohr a. J Clin Oncol. 2006 Dec 1;24(34):5343-9. doi: 10.1200/JCO.2005.05.0401. Epub 2006 Nov 6. J Clin Oncol. 2006. PMID: 17088571 Clinical Trial.
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.
Chanan-Khan A, Miller KC, Musial L, Padmanabhan S, Yu J, Ailawadhi S, Sher T, Mohr A, Bernstein ZP, Barcos M, Patel M, Iancu D, Lee K, Czuczman MS. Chanan-Khan A, et al. Among authors: mohr a. Leuk Lymphoma. 2009 Jul;50(7):1096-101. doi: 10.1080/10428190902912460. Leuk Lymphoma. 2009. PMID: 19479618 Clinical Trial.
Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, Skipper M, Brown K, Miller K, Wentling D, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-López AJ, Bernstein SH. Czuczman MS, et al. Among authors: mohr a. Semin Oncol. 2002 Feb;29(1S2):36-40. doi: 10.1053/sonc.2002.30152. Semin Oncol. 2002. PMID: 28140090
Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.
Torka P, Akhtar OS, Reddy NM, Baysal BE, Kader A, Groman A, Nichols J, Mavis C, Tario JD, Block AW, Sait SNJ, Ghione P, Sundaram S, Przespolewski ER, Mohr A, Lund I, Kostrewa J, McWhite K, DeMarco J, Johnson M, Darrall A, Thomas-Talley RN, Wallace PK, Neppalli V, Hutson A, Hernandez-Ilizaliturri FJ. Torka P, et al. Among authors: mohr a. Cancer. 2022 Apr 15;128(8):1595-1604. doi: 10.1002/cncr.34106. Epub 2022 Feb 14. Cancer. 2022. PMID: 35157306 Free PMC article. Clinical Trial.
Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.
Torka P, Groman A, Wong J, Nichols J, Kader A, Mavis C, Anampa-Guzmán A, Sait SJ, Block A, Przespolewski E, Mohr A, Lund I, McWhite K, Kostrewa J, DeMarco J, Johnson M, Darrall A, Thomas R, Sundaram S, Ghione P, Hutson A, Hernandez-Ilizaliturri FJ. Torka P, et al. Among authors: mohr a. Blood Adv. 2023 Apr 11;7(7):1146-1155. doi: 10.1182/bloodadvances.2022008543. Blood Adv. 2023. PMID: 36375132 Free PMC article. Clinical Trial.
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.
Ghione P, Gu JJ, Attwood K, Torka P, Goel S, Sundaram S, Mavis C, Johnson M, Thomas R, McWhite K, Darrall A, DeMarco J, Kostrewa J, Mohr A, Rivas L, Neiders M, Suresh L, Segal BH, Griffiths EA, Ramsperger V, Shen L, Hernandez-Ilizaliturri FJ. Ghione P, et al. Among authors: mohr a. Blood. 2021 Sep 2;138(9):811-814. doi: 10.1182/blood.2021012443. Blood. 2021. PMID: 34189565 Free PMC article. No abstract available.
650 results